Enteral nutrition in cystic fibrosis

Angelika Kędzior1, Beata Łabuz-Roszak2, Sylwia Jezierska3

  • 1Katedra i Zakład Podstawowych Nauk Medycznych, Wydział Zdrowia Publicznego w Bytomiu, Śląski Uniwersytet Medyczny w Katowicach, Bytom, Polska

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|January 27, 2020
PubMed

Insights

Enteral nutrition significantly benefits cystic fibrosis patients who struggle with weight gain on high-energy diets. This method improves quality of life and reduces respiratory infections with minimal side effects.

Area of Science:

  • Medical Science
  • Nutrition Science
  • Genetics

Background:

  • Cystic fibrosis (CF) is a genetic disorder requiring comprehensive management.
  • Early detection through newborn screening enables prompt treatment.
  • Nutritional support is a critical component of CF therapy.

Purpose of the Study:

  • To evaluate the benefits and risks of enteral nutrition in cystic fibrosis patients.
  • To assess the impact of enteral nutrition on weight, quality of life, and infection rates in CF patients.

Main Methods:

  • A study involving 53 cystic fibrosis patients (15 males, 38 females).
  • Inclusion criteria: at least one month of enteral nutrition, underweight, and no weight gain on high-energy oral diet.
  • Data collected using a self-constructed questionnaire.

Main Results:

  • Median weight gain of 7 kg was observed with enteral nutrition.
  • Over 79% reported no side effects; minor issues included local infections and balloon prolapse.
  • All patients reported benefits, primarily weight gain and improved quality of life.
  • 41.5% experienced a decrease in respiratory infection frequency.

Conclusions:

  • Enteral nutrition is an effective strategy for cystic fibrosis patients unresponsive to high-energy oral diets.
  • It leads to significant weight gain, enhanced quality of life, and potentially fewer respiratory infections.
  • The method is well-tolerated with a low incidence of adverse events.
Abstract

Related Concept Videos

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
688
Enteral Nutrition I: Orogastric and Nasogastric Feeding01:26

Enteral Nutrition I: Orogastric and Nasogastric Feeding

Enteral nutrition delivers nutrients directly to the stomach or small intestine through a tube. This method is appropriate for patients who cannot eat but still have a functioning digestive system. It is also beneficial for individuals with swallowing difficulties, anorexia, malabsorption, or those who have undergone gastrointestinal (GI) surgery.
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
1.0K
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
625
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
400
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
565
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
283